Postbiotics: 4 Strains with Solid Scientific Evidence

En bref — Few postbiotics have solid clinical evidence. The most robust data concern Lactobacillus LB (Lacteol), a pasteurised Akkermansia muciniphila, and tyndallised Bifidobacterium bifidum MIMBb75, each backed by at least one randomised controlled trial in humans. The ISAPP 2021 definition is the reference, and any dossier must name the strain, not the family.

Searching for scientific evidence on postbiotics often turns up generic lists, rarely a named clinical trial. The reality is narrower: today, only four strains or preparations are backed by a published randomised controlled trial in humans for gut health. The reference definition comes from ISAPP (International Scientific Association for Probiotics and Prebiotics), published in 2021 in Nature Reviews Gastroenterology & Hepatology [1]. For your R&D files, the level of evidence is never judged by the “postbiotic” family as a whole, but by the strain and its protocol.

The verdict: four strains hold up, the rest is marketing

A postbiotic is a preparation of inactivated micro-organisms and/or their components that confers a health benefit on the host. This is the ISAPP 2021 definition [1]. It excludes isolated purified metabolites (short-chain fatty acids alone, for example) and requires that the micro-organism was first alive, then inactivated under controlled conditions. This distinction changes everything for a regulatory file.

Apply this filter to genuinely documented postbiotics, and the list shrinks. Four strains have at least one randomised controlled trial in humans behind them: Lactobacillus LB (Lacteol), a pasteurised Akkermansia muciniphila, tyndallised Bifidobacterium bifidum MIMBb75, and a heat-killed preparation of Lactobacillus paracasei MCC1849. Everything else rests on preclinical data, animal models, or extrapolation from the live strain.

For your R&D, the message is clear: a claim built on the “postbiotic family” will not survive EFSA scrutiny. The level of evidence is negotiated strain by strain, trial by trial.

Why are postbiotics gaining ground now?

This progress stems from three concrete industrial pressures. First, stability: an inactivated micro-organism can no longer die. It withstands heat, humidity and long shelf life without a cold chain, whereas a live probiotic loses CFU at every formulation step. For your tablet, beverage or functional snack ranges, this widens the range of possible matrices.

Second, safety. EFSA classified Akkermansia muciniphila pasteurised as a Novel Food in 2021, authorising its placement on the European market at defined doses [2]. An inactivated organism raises fewer questions about translocation or resistance than its live version, a useful argument for vulnerable populations.

Finally, the market. According to Grand View Research (2024 report), the postbiotic segment showed double-digit annual growth, driven by demand for long-shelf-life ingredients [3]. This figure comes from a market research firm, not an official registry: treat it as a directional signal, not a validated projection. What is verifiable, however, is the pace of clinical publications, which has risen steadily since the ISAPP definition.

Postbiotics: what scientific evidence exists for each strain?

Lactobacillus LB (the heat-killed strain in Lacteol) is the oldest dossier. Several randomised controlled trials have documented a reduction in the duration of acute diarrhoea, particularly in children, with favourable tolerability [4]. It is the postbiotic preparation with the longest clinical track record.

For pasteurised Akkermansia muciniphila, the reference trial from the Louvain team (UCLouvain, Cani and colleagues) showed, over 3 months in overweight subjects, an improvement in metabolic markers and insulin sensitivity. The pasteurised form performed at least as well as the live one [5]. Its relevance to gut health lies in its action on the mucus layer.

Tyndallised (heat-inactivated) Bifidobacterium bifidum MIMBb75 reduced the overall severity of irritable bowel syndrome symptoms in a randomised controlled trial published in The Lancet Gastroenterology & Hepatology [6]. The result that matters: the inactivated form retained the efficacy observed with the live strain.

A first meta-analysis published in 2026 in the Journal of Gastroenterology and Hepatology confirms the trend on a larger scale: across 4 randomised controlled trials and 1,062 adults, the IBS severity score (IBS-SSS) fell markedly, and the likelihood of responding on pain was multiplied by 2.46. The authors nonetheless rate the certainty of evidence as low, owing to moderate-to-high heterogeneity between the strains tested [7]. This is, to date, the best-supported gut benefit for the postbiotic category as a whole. It does not exempt you from requiring the trial specific to your own strain.

Here is how these dossiers compare on the criteria that matter for a brief:

Read this table as a risk hierarchy for your dossiers: the more substantial the “level of evidence” column, the less exposed your claims dossier is.

Obstacles to anticipate before adding a strain to your specifications

The obstacles are real, and they arise early in the project. It is best to address them in order:

1. Semantic confusion. “Inactivated”, “tyndallised”, “heat-killed” and “paraprobiotic” are not interchangeable. A dossier that mixes these terms signals a lack of rigour to the assessor. Fix the ISAPP terminology from the brief stage onward.
2. No validated health claim. To date, no specific “postbiotic” health claim has passed EFSA evaluation under Regulation 1924/2006. Dossiers move forward through Novel Food (market authorisation) [2], not through an effect claim. Do not sell a health benefit that the framework does not yet permit.
3. Strain specificity. Data from MIMBb75 does not transfer to another B. bifidum. Each strain requires its own evidence. A study published in 2025 in Microorganisms illustrates this starkly: of five commercial postbiotics compared under identical conditions, only one triggered interferon-alpha production, a key marker of the antiviral response. The other four, despite being marketed with the same immune-support claims, showed no measurable effect on this criterion [8].
4. Process reproducibility. The method of inactivation alters the structure of the active components. Two “heat-killed” batches produced at different temperatures are not equivalent. Document the process as a specification parameter.
5. Trial funding. A methodological review published in 2026 in Molecular Nutrition & Food Research notes that tested doses range from 10⁹ to 4×10¹¹ cells depending on the trial, that inactivation methods are often poorly described, and that a significant proportion of clinical trials are funded by the manufacturer of the strain being tested. Demand the full protocol from your supplier, not just the conclusion in the abstract [9].

These five points determine whether your dossier holds up or collapses at the first regulatory review.

What this evidence-based sorting means for your teams

Sorting by the scientific evidence that governs postbiotics changes the purchasing conversation. For your ingredient buyers, the question stops being “do you have a postbiotic?” and becomes “which strain, which trial, which population, which documented inactivation process?” A supplier who cannot cite a named trial on their own strain is selling a marketing argument, not an ingredient.

For your R&D, the scarcity of solid dossiers is an opportunity: the field remains open for strains that invest in their own clinical trial. The scientific barrier to entry is high, and therefore defensible once cleared.

For your marketing, discipline is essential: communicate about the documented strain, reference the trial, and stay within the scope the regulatory framework permits. This is also what makes content citable by AI search engines, which favour answers attributed to a named source.

One question remains to ask every supplier before signing: on which population, and at exactly what dose, did your trial measure the effect you are promoting?

References

1. Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649-667.
2. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of pasteurised Akkermansia muciniphila as a novel food. EFSA Journal. 2021;19(9):6780.
3. Grand View Research. Postbiotics Market Size & Trends Report. 2024. (Tier 3, to be verified)
4. Xiao SD, Zhang DZ, Lu H, et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther. 2003;20(5):253-260.
5. Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-1103.
6. Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5(7):658-666.
7. Meta-analysis of 4 randomised controlled trials on postbiotics and irritable bowel syndrome (n = 1,062). J Gastroenterol Hepatol. 2026.
8. Comparative study of five commercial postbiotics on interferon-alpha induction. Microorganisms. 2025.
9. Methodological review of dose and inactivation process heterogeneity in clinical trials on postbiotics. Mol Nutr Food Res. 2026.